Xeris Biopharma Holdings (XERS) Free Cash Flow (2020 - 2026)
Xeris Biopharma Holdings (XERS) posted Free Cash Flow of $9.9 million for Q1 2026, down 50.76% on a QoQ basis from $20.0 million in Q4 2025, and up 198.39% year-over-year from $3.3 million in Q1 2025.
Xeris Biopharma Holdings (XERS) Free Cash Flow (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings' Free Cash Flow history runs 7 years deep, the most recent figure standing at $9.9 million for Q1 2026.
- Quarterly Free Cash Flow rose 198.39% year-over-year to $9.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.5 million (up 281.69% YoY) and the FY2025 annual result came in at $28.6 million, up 177.41% from the prior year.
- Free Cash Flow was $9.9 million for Q1 2026 at Xeris Biopharma Holdings, down from $20.0 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $20.0 million in Q4 2025 and bottomed at -$48.4 million in Q1 2022.
- A 5-year average of -$8.7 million and a median of -$10.3 million in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow slumped 102.07% — and 2025, when it soared 914.84%.
- Xeris Biopharma Holdings' Free Cash Flow stood at -$16.1 million in 2022, then soared by 146.35% to $7.5 million in 2023, then plunged by 73.56% to $2.0 million in 2024, then surged by 914.84% to $20.0 million in 2025, then plunged by 50.76% to $9.9 million in 2026.
- Business Quant data shows XERS's Free Cash Flow at $9.9 million in Q1 2026, $20.0 million in Q4 2025, and $18.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -208.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 291.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -373.37 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 363.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 348.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 144.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -38.00 Mn |
| 10 | Xeris Biopharma Holdings | 1.43 Bn | 1.32 Bn | 72.55 Mn | 9.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.87 Mn |
| Mar 31, 2026 | 9.87 Mn |
| Dec 31, 2025 | 20.04 Mn |
| Dec 31, 2025 | 20.04 Mn |
| Sep 30, 2025 | 18.43 Mn |
| Sep 30, 2025 | 18.43 Mn |
| Jun 30, 2025 | 182,000.00 |
| Jun 30, 2025 | 182,000.00 |
| Mar 31, 2025 | -10.03 Mn |
| Mar 31, 2025 | -10.03 Mn |
| Dec 31, 2024 | 1.98 Mn |
| Dec 31, 2024 | 1.98 Mn |
| Sep 30, 2024 | -8.31 Mn |
| Sep 30, 2024 | -8.31 Mn |
| Jun 30, 2024 | -10.35 Mn |
| Jun 30, 2024 | -10.35 Mn |
| Mar 31, 2024 | -20.30 Mn |
| Mar 31, 2024 | -20.30 Mn |
| Dec 31, 2023 | 7.47 Mn |
| Dec 31, 2023 | 7.47 Mn |